These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 29445409)
1. Suvorexant for insomnia in older adults: a perspective review. Tampi RR; Manikkara G; Balachandran S; Taparia P; Hrisko S; Srinivasan S; Tampi DJ Drugs Context; 2018; 7():212517. PubMed ID: 29445409 [TBL] [Abstract][Full Text] [Related]
2. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia. Patel KV; Aspesi AV; Evoy KE Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197 [TBL] [Abstract][Full Text] [Related]
4. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Kuriyama A; Tabata H Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447 [TBL] [Abstract][Full Text] [Related]
5. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826 [TBL] [Abstract][Full Text] [Related]
6. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664 [TBL] [Abstract][Full Text] [Related]
7. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Kishi T; Matsunaga S; Iwata N PLoS One; 2015; 10(8):e0136910. PubMed ID: 26317363 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372 [TBL] [Abstract][Full Text] [Related]
9. Review of Safety and Efficacy of Sleep Medicines in Older Adults. Schroeck JL; Ford J; Conway EL; Kurtzhalts KE; Gee ME; Vollmer KA; Mergenhagen KA Clin Ther; 2016 Nov; 38(11):2340-2372. PubMed ID: 27751669 [TBL] [Abstract][Full Text] [Related]
10. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Citrome L Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363 [TBL] [Abstract][Full Text] [Related]
11. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data. Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875 [TBL] [Abstract][Full Text] [Related]
12. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data. Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715 [TBL] [Abstract][Full Text] [Related]
13. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752 [TBL] [Abstract][Full Text] [Related]
14. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953 [TBL] [Abstract][Full Text] [Related]
15. Analgesics in the management of behavioral and psychological symptoms of dementia: a perspective review. Tampi RR; Hassell C; Joshi P; Tampi DJ Drugs Context; 2017; 6():212508. PubMed ID: 29209402 [TBL] [Abstract][Full Text] [Related]
16. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics. Janto K; Prichard JR; Pusalavidyasagar S J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886 [TBL] [Abstract][Full Text] [Related]
17. Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant. Khazaie H; Sadeghi M; Khazaie S; Hirshkowitz M; Sharafkhaneh A Front Psychiatry; 2022; 13():1070522. PubMed ID: 36578296 [TBL] [Abstract][Full Text] [Related]
18. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts. Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763 [TBL] [Abstract][Full Text] [Related]
19. Acupuncture for insomnia. Cheuk DK; Yeung WF; Chung KF; Wong V Cochrane Database Syst Rev; 2007 Jul; (3):CD005472. PubMed ID: 17636800 [TBL] [Abstract][Full Text] [Related]